Get the Stockscreener App
1.77
3.80%
-0.07
Pre-market:
1.78
0.01
+0.56%
Outlook Therapeutics Inc stock is traded at $1.77, with a volume of 1.77M.
It is down -3.80% in the last 24 hours and up +14.19% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.84
Open:
$1.89
24h Volume:
1.77M
Relative Volume:
3.62
Market Cap:
$75.84M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.4425
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+10.62%
1M Performance:
+14.19%
6M Performance:
-12.81%
1Y Performance:
-74.96%
1-Day Range:
$1.735
$1.8999
1-Week Range:
$1.5506
$1.90
52-Week Range:
$0.87
$9.25
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.77 | 68.99M | 0 | -51.50M | -47.10M | -4.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Northern Trust Corp Sells 7,119 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD - marketscreener.com
Outlook Therapeutics (OTLK) Launches LYTENAVA in European Markets | OTLK Stock News - GuruFocus
Outlook Therapeutics Launches LYTENAVA For Patients With Wet AMD In Germany And The UK - Nasdaq
Outlook Therapeutics launches LYTENAVA in Germany and UK By Investing.com - Investing.com India
Outlook Therapeutics® Announces Commercial Launch of - GlobeNewswire
Outlook Therapeutics launches LYTENAVA in Germany and UK - Investing.com UK
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - Yahoo Finance
Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst - Defense World
Brokers Issue Forecasts for OTLK FY2026 Earnings - Defense World
Metric Analysis: Outlook Therapeutics Inc (OTLK)’s Key Ratios in the Limelight - DWinneX
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $10.20 Average Target Price from Brokerages - Defense World
Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks
Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus
Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus
Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering - marketscreener.com
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire
Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan
Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus
Outlook Therapeutics Reports Improved Financials Amid Challenges - TipRanks
Outlook Therapeutics Plans Share Offering; Stock Declines After Hours - marketscreener.com
Outlook Therapeutics announces public stock offering - Investing.com Australia
Outlook Therapeutics announces public stock offering By Investing.com - Investing.com Nigeria
Outlook Therapeutics (OTLK) Launches Public Offering of Stock and Warrants | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Comm - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - The Manila Times
Outlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants - Nasdaq
Outlook Therapeutics (OTLK) Sees Price Target Reduced by Guggenheim Analyst | OTLK Stock News - GuruFocus
Outlook Therapeutics (NASDAQ:OTLK) vs. Novavax (NASDAQ:NVAX) Head-To-Head Survey - Defense World
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
Outlook Therapeutics (OTLK) Poised for European and U.S. Market Expansion | OTLK Stock News - GuruFocus
Outlook Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
Outlook Therapeutics Eyes Major Transformation: European Launch and FDA Decision Set for 2025 - Stock Titan
Outlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on Wednesday - Defense World
Renaissance Technologies LLC Acquires New Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Russell Investments Group Ltd. Boosts Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
INVESTOR ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):